1IA
HZNP

1834 Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

1834 Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-137
Closed -$8K – 487
2020
Q2 		$8K Buy
+137
New +$5.86K ﹤0.01% 351

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

1834 Investment Advisors's HZNP Position: Q3 2020 in Review

1834 Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2020, closing a stake of 137 shares — an estimated $8K sold.

1834 Investment Advisors first reported a position in HZNP in Q2 2020 and held it in 1 quarter. The position peaked at $8K in Q2 2020. 433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

  • 1834 Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2020 after selling out during the quarter.
  • 1834 Investment Advisors sold 137 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2020, an estimated $8K.
  • 1834 Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 1 quarter.
  • 1834 Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8K in Q2 2020.
  • 433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on 1834 Investment Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.